Sellas Life Sciences Group Inc
(SLS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 0 | 0 | 1,000 | 7,600 | 1,900 |
| Cost of Goods | N/A | N/A | 100 | 200 | N/A |
| Gross Profit | N/A | N/A | 900 | 7,400 | 1,900 |
| Operating Expenses | 31,513 | 37,869 | 42,950 | 32,894 | 18,882 |
| Operating Income | -31,513 | -37,869 | -41,950 | -25,294 | -16,982 |
| Other Income | 632 | 529 | 649 | 4,358 | 208 |
| Pre-tax Income | -30,881 | -37,340 | -41,301 | -20,936 | -16,774 |
| Income Tax | N/A | N/A | N/A | -237 | -17 |
| Net Income Continuous | -30,881 | -37,340 | -41,301 | -20,699 | -16,757 |
| Net Income | $-30,881 | $-37,340 | $-41,301 | $-20,699 | $-16,757 |
| EPS Basic Total Ops | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 |
| EPS Basic Continuous Ops | -0.50 | -1.34 | -2.13 | -1.34 | -2.10 |
| EPS Diluted Total Ops | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 |
| EPS Diluted Continuous Ops | -0.50 | -1.34 | -2.13 | -1.34 | -2.10 |
| EPS Diluted Before Non-Recurring Items | -0.50 | -1.34 | -2.13 | -1.34 | -2.11 |
| EBITDA(a) | $-31,513 | $-37,869 | $-41,950 | $-25,294 | $-16,700 |